Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

A graduate of Stanford University's prestigious EENT Innovation Biodesign program in 2019, Diag-Nose.io is redefining ...

Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today ...

L'Oréal -backed biotech firm Debut has released an artificial intelligence (AI)-powered ingredient discovery platform aimed ...

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

From a margin perspective, Danaher's operations should eventually improve once top-line growth rebounds. With that operating leverage-related margin expansion, we expect Danaher's adjusted EPS to grow ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Trilobio, developer of whole lab automation solutions for advancing biology research, today introduced the first version of ...

Enhanc3D Genomics launched a suite of 3D multi-omics solutions to accelerate drug development during a presentation at last ...

BeautyORB will help create 2 biotech ingredients per year, with current plans for anti-aging, brightening, and scalp care ...